The Guardian - Pharmaceutical Industry

SEPTEMBER 9, 2023

Thanks to booming demand for its weight loss treatment Wegovy, the Danish business last week became Europe’s biggest company by stock market value, overtaking the previous holder of that title, French luxury group LVMH. Novo Nordisk’s stock market value of £340bn now exceeds Denmark’s entire economic output , estimated at £323bn this year.

63

63

The FDA Law Blog

SEPTEMBER 26, 2023

Grizzel will oversee the marketing organization, with responsibility for continuing and enhancing HP&M’s brand and expanding its business development activities. Jeff joins HP&M from Compliance Architects where he served as Vice President of Business Development.

FDA 59

FDA 59

Pharmaceutical Technology

JULY 6, 2022

Business optimism improved in June 2022 compared to May 2022, even amid concerns over rising costs and slowing demand, revealed an analysis of an ongoing poll by Verdict. Business confidence remains equivalent to long-term average in the UK. The East of England reported the highest increase in business confidence from 14% to 31%.

52

52

European Pharmaceutical Review

FEBRUARY 1, 2023

An increase in the number of drug launches and rising investment in R&D contributed to the growth of the market, found the Business Research Company, who produced the report. Recent geopolitical war has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruption. billion in 2022 to $1.29

Compounding 83

Compounding 83

pharmaphorum

NOVEMBER 18, 2020

To mark World Antimicrobial Awareness Week NovaBiotics’s Deborah O’Neil tells us why 2021 might be the year anti-infective drugs finally demonstrate their economic value. . COVID-19 has reminded the world how critical infectious disease is, from both a societal and economic standpoint. We need to keep up the momentum.

Communication 104

Communication Immunization 104

pharmaphorum

APRIL 1, 2022

The webinar will also cover: Up to date analysis of political, economic, social, technological, environmental, and legal factors surrounding the new legislation. He holds a Master’s degree in health economics and is an alumni of the Henley Business School. Key issues keeping pharma and ICS awake at night. About the panel.

95

95

Pharmaceutical Technology

AUGUST 4, 2022

Business optimism declined in July 2022 compared to June 2022, amid concerns over inflation as the cost-of-living pressures on households continued to grow in countries such as the UK, revealed the analysis of an ongoing poll by Verdict. Business confidence falls three points to 25% in the UK. believed it would decrease.

Hospitals 52

Hospitals 52

Pharmaceutical Technology

OCTOBER 7, 2022

Business optimism decreased in September 2022 compared to August 2022, according to an ongoing poll by Verdict, amidst businesses expressing concerns about rising inflation and its impact on the overall economy. Australia’s business sentiment dips to lowest levels since April 2020. Business optimism declined to 105.2

52

52

pharmaphorum

NOVEMBER 6, 2022

Lilly had already secured planning approval from Limerick City and County Council for the plant at the Raheen Business Park. However, an appeal against the decision by a local farmer – citing concerns about his land being flooded with contaminated water – has been upheld, according to a Limerick Post report.

104

104

NICE

MAY 30, 2023

Development of economic evaluations and implementation support tools NICE plans to publish an update of the economics evidence that supports its clinical guideline (NG94) on emergency and acute medical care (for over 16s). This will include guidance and advice on future priorities for data collection.

Hospitals 52

Hospitals 52

Pharmaceutical Technology

SEPTEMBER 6, 2022

Business optimism improved in August 2022 compared to July 2022, according to an ongoing poll by Verdict, despite businesses expressing concern over inflation, particularly in raw materials and energy costs. Business confidence improves in three of the UK’s regions. Indian firms witness stronger growth and softer cost pressures.

52

52

ISPE

JULY 14, 2023

Our Understanding of the Smart Industry Readiness Framework (SIRI) The Smart Industry Readiness Index (SIRI) is a comprehensive framework developed by the Singapore Economic Development Board (EDB). Additionally, there is limited interaction with business stakeholders, which can hinder obtaining business buy-in at a later stage.

Documentation 98

Documentation 98

ISPE

DECEMBER 7, 2022

Digitalization in Business Processes that Support Sustainability & Economy of Means, Power & Led By Women in Pharma®. Digitalization in Business Processes that Support Sustainability & Economy of Means, Power & Led By Women in Pharma®. Trudy Patterson. Wed, 12/07/2022 - 08:27. iSpeak Blog. 7 December 2022. Watch Webinar.

52

52

pharmaphorum

FEBRUARY 28, 2022

A new study has suggested that the economic burden posed by rare diseases is around 10 times higher than for common “mass market” conditions. Extrapolating the cost for 8.4 million patients in the US impacted by more than 370 rare diseases modelled in the analysis comes to $2.2 trillion annually, and between $7.2 trillion and $8.6

Documentation 98

Documentation Hospitals 98

pharmaphorum

FEBRUARY 12, 2021

Rory Mullen, head of biopharma at Ireland’s economic development agency IDA Ireland tells pharmaphorum why business is blossoming in the Emerald Isle. While business could be challenging as travel restrictions ensue, Mullen is optimistic. “We

Packaging 123

Packaging Pharmaceutical Companies Pharmaceutical Companies 123

pharmaphorum

AUGUST 16, 2022

In this article, Ben Hargreaves looks at how companies have reacted to an unfavourable economic climate and what that could mean for the long-term growth of the industry. Being able to continue such momentum as a normal economic environment re-emerged would have been difficult, as people began to resume their usual routines.

52

52

pharmaphorum

MARCH 4, 2021

In the meantime, a 130% business tax “super deduction” for capital investment in new equipment will help companies including life sciences rebuild capacity. There were other measures aimed at boosting the life sciences industry, which has seen record levels of investment during the pandemic.

Vaccines 104

Vaccines Immunization FDA 104

pharmaphorum

DECEMBER 21, 2022

For businesses, limiting global warming to 1.5˚C The final agreement has in principle kept this goal alive, but in reality – given the current trajectory of emissions forecasts – it could be statistically unlikely that business will be able to commit to this. We’re fresh off the back of the COP27 summit in Egypt.

97

97

pharmaphorum

NOVEMBER 27, 2020

Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. That was among the discussion points during Fighting Rare Diseases – The Science, Economics and the Patients , a webinar hosted by o2h Group.

132

132

European Pharmaceutical Review

MARCH 7, 2024

Bates also commented on the R&D tax relief regime: “Successive policy changes to the R&D tax regime over the past several years have created uncertainty and additional red-tape for SMEs, putting at risk the UK’s reputation as a location for innovative businesses.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies Packaging Vaccines 97

European Pharmaceutical Review

APRIL 27, 2023

His contributions “have been integral in the evolution of our portfolio over the past several years, notably building our leading presence in immuno-oncology, growing our CV business and launching multiple new medicines,” Samuels added. He holds a BA in economics and history from Washington University in St Louis, US.

72

72

STAT

AUGUST 2, 2023

And what better way to make the time fly than to keep busy. taxpayers $82,500 per patient per year, on average, for genetic tests, frequent brain scans, safety monitoring, and other care, according to the Institute for Clinical and Economic Review, or ICER. The middle of the week is upon us. Have heart, though.

Insurance Coverage 73

Insurance Coverage Insurance 73

pharmaphorum

FEBRUARY 17, 2021

The membership of the conference included healthcare professionals specialising in medicine, dentistry, pharmacy, economics, administration, and in other relevant disciplines. At an individual level, the story is everyone doing the “right thing” to protect and grow their businesses, brands, and shareholders.

Insurance 125

Insurance Pharmaceutical Companies Pharmaceutical Companies 125

STAT

OCTOBER 6, 2022

Rise and shine, everyone, another busy day is on the way.  Even a drug-price watchdog, the Institute for Clinical and Economic Review, deemed the $2.8 And this is especially true for us, since we hit the proverbial pause button yesterday to observe ancient rituals. Now, though, we have returned and there is much to do.

74

74

European Pharmaceutical Review

JULY 7, 2023

Specifically, the reports “provide crucial insights into the needs, challenges and opportunities of these important sectors and the scope for industry, academia and government to work together to boost their productivity and drive economic growth,” according to Professor Francisco Veloso, Dean of Imperial College Business School.

Compounding 87

Compounding Pharmaceutical Companies Pharmaceutical Companies 87

pharmaphorum

NOVEMBER 3, 2022

Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences. The Ireland-domiciled company said the move would provide the benefit of two distinct management teams with the therapeutic expertise to drive the two businesses forward.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

JULY 26, 2022

“We will disrupt the economics of the drug business by allowing a wide pool of innovators and contributors, rather than only pharmaceutical giants, to profit from drug discovery.” ” The post Despite ban, Martin Shkreli can’t seem to kick the pharma habit appeared first on.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Fuld

MARCH 30, 2021

Christian Schena brings prolific relationship-building, sales consulting, lead generation, and business development experience to the firm. After more than 20 years advising business leaders and executives, Schena joins Fuld + Company most recently from global information provider IHS Markit, where he served as the Sr. Boston, Mass.

59

59

pharmaphorum

DECEMBER 16, 2022

million that the Institute for Clinical and Economic Review (ICER) said would be a fair maximum price in an earlier report. Last year, another gene therapy developer – bluebird bio – pulled out of the EU market altogether, saying pricing policies had made it impossible to develop a viable business there.

FDA 118

FDA 118

Fuld

NOVEMBER 1, 2022

BOSTON – Nov 1, 2022 – Fuld & Company, a fast-growing research, analytics, and advisory business, today announced the appointment of Brad Thompson to the role of Advisory Board Member. Based in Philadelphia, PA, Brad holds an MBA from the Fairleigh Dickinson University and a BA in Economics from University of Pittsburgh.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 24, 2023

These CMOs showed an increasing reluctance to take on debt even before the rising inflation and interest rates seen last year, perhaps due to taking a more cautious approach during the uncertain business environment caused by the Covid-19 pandemic. As a consequence, loans became less attractive for businesses to acquire.

59

59

pharmaphorum

OCTOBER 13, 2020

Ayming surveyed a combination of 330 business executives and R&D managers from 13 countries across North America and Europe. All the same, the growing technical nature of R&D means businesses are looking for outside support, with use of external private resources up from 35% to 48%.

109

109

Pharmaceutical Technology

APRIL 28, 2023

Increased drug shortages, the exposure of supply chain vulnerabilities by the Covid-19 pandemic, and economic and political drivers have contributed to calls for more home-grown API. This new API business is Sanofi’s ‘Made in Europe’ solution and has eight facilities in the UK, France, Germany, Italy, and Hungary.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

NOVEMBER 30, 2023

o find out about the current trends in cell and gene therapy manufacturing, EPR spoke to Cell and Gene Therapy Catapult (CGT Catapult)’s Chief Manufacturing Officer, Stephen Ward, and Chief Business Officer, Jeanette Evans. Specifically: “digital skills are coming through as a growing concern for businesses”.

Medical Schools 77

Medical Schools 77

pharmaphorum

NOVEMBER 4, 2021

Roche CEO Christoph Franz said meanwhile that the deal “is in the best interest of Roche and the holders of Roche equity securities from a strategic and economic perspective.” Novartis has already spun off eyecare unit Alcon, and is now looking into the future of its Sandoz generics business.

104

104

pharmaphorum

JUNE 6, 2022

The addition to the company’s portfolio – which already spans services like patient support, digital engagement, dispensing and distribution, and data/analytics – has arrived on the back of an alliance with business and wellness coaching specialist Limitless Minds.

103

103

European Pharmaceutical Review

SEPTEMBER 29, 2022

Another contributing factor to drug shortages cited by the Task Force was the economic landscape and market structure under which pharmaceutical manufacturing takes place. Can continuous manufacturing add shareholder value for pharmaceutical companies?

Nursing Homes 79

Nursing Homes Department of Veterans Affairs FDA Dosage 79